Stocklytics Platform
Asset logo for symbol SRRK
Scholar Rock Holding
SRRK48
$34.60arrow_drop_up0.14%$0.05
Asset logo for symbol SRRK
SRRK48

$34.60

arrow_drop_up0.14%
Key Stats
Open$35.00
Prev. Close$34.55
EPS-2.47
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range33.27
39.57
52 Week Range6.48
47.99
Ratios
Revenue-
EBITDA Margin %-
EPS-2.47
Fundamentals
RPS-
Gross Profit-
Payout Ratio-
Industry average yield2.92%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

SRRK-
US Healthcare Sector-
US Market-
warning

SRRK / Market

SRRK lose to the US Market which returned 2.09% over the last twenty four hours.
warning

SRRK / Healthcare Sector

SRRK lose to the US Healthcare sector which returned 3.60% over the last twenty four hours.

Scholar Rock Holding (SRRK) Statistics

The valuation metrics of Scholar Rock Holding Corp (SRRK) provide insight into the market perception of the company's worth. These metrics help investors assess whether the stock is overvalued or undervalued relative to its fundamentals. One important metric is the price-to-earnings ratio (P/E), which compares the stock price to the company's earnings per share. Another metric is the price-to-sales ratio (P/S), which compares the stock price to the company's revenue per share. These valuation metrics can help investors determine whether the stock is priced attractively or not.
Scholar Rock Holding Corp (SRRK) is a biopharmaceutical company focused on the discovery and development of innovative medicines that target the TGF-beta superfamily of proteins. The company's pipeline includes potential treatments for a range of serious diseases, including cancer, fibrosis, and musculoskeletal disorders. Scholar Rock's approach is based on its proprietary platform, which leverages the unique properties of the TGF-beta superfamily to develop highly specific and potent therapeutics. The company's goal is to transform the lives of patients by harnessing the therapeutic potential of this important class of proteins.
add Scholar Rock Holding to watchlist

Keep an eye on Scholar Rock Holding

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Scholar Rock Holding (SRRK) stock's performance compared to its sector and the market over the past year?

Over the past year, Scholar Rock Holding (SRRK) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 20.50%, Scholar Rock Holding has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 34.29%, it has fallen short of the market average. This comparison highlights Scholar Rock Holding's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Scholar Rock Holding (SRRK) stock?

The PE ratio for Scholar Rock Holding (SRRK) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Scholar Rock Holding (SRRK) stock?

The Earnings Per Share (EPS) for Scholar Rock Holding (SRRK), calculated on a diluted basis, is -$2.47. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Scholar Rock Holding (SRRK) stock?

The operating margin for Scholar Rock Holding (SRRK) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Scholar Rock Holding (SRRK) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Scholar Rock Holding (SRRK) is -$250.12M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Scholar Rock Holding (SRRK) have?

Scholar Rock Holding (SRRK) has a total debt of $65.13M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$112.75M.

Take Your Investments to a Whole New Level